Branded

Konvomep is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.

Spevigo is the first approved treatment option for generalized pustular psoriasis flares in adults.

Pemazyre is the first targeted treatment approved for use in the United States for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Auvelity is the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults.

​​​​​​​Zoryve is a next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis.

Lilly’s citrate-free formulation of Taltz significantly reduces injection site pain, the company said.

Myfembree is a once-daily treatment for the management of moderate to severe pain associated with endometriosis.

Enhertu is the first approved therapy targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.

Stelara provides a new therapeutic option for children six years of age and older living with active psoriatic arthritis.

Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis.

Opzelura is the first and only FDA-approved treatment for repigmentation in patients with vitiligo, and the only topical formulation of a Janus kinase inhibitor approved in the United States.

ProvayBlue is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.